Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPX-629
- Development stage
- Preclinical
- Lead developer
- Keba Biological
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SPX-629 is a next-generation antibody-drug conjugate (ADC) developed by SparX Biotech that targets the Human Epidermal Growth Factor Receptor 2 (HER2). It utilizes a proprietary dual-payload platform (Nab2) to deliver two distinct cytotoxic agents: a Topoisomerase 1 (TOP1) inhibitor and Monomethyl auristatin E (MMAE). By combining these two mechanisms of action—DNA damage and microtubule inhibition—SPX-629 is designed to enhance anti-tumor activity and overcome potential resistance mechanisms associated with single-payload ADCs. The candidate is currently in the IND-enabling stage of development for the treatment of HER2-expressing solid tumors.
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on SPX-629.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPX-629.